Skip to main content
. Author manuscript; available in PMC: 2013 Sep 15.
Published in final edited form as: Clin Cancer Res. 2012 Jul 25;18(18):4942–4953. doi: 10.1158/1078-0432.CCR-11-2805

Figure 2.

Figure 2

UA enhances the ability of capecitabine to inhibit the growth of orthotopically implanted CRC tumors in nude mice. (A) Schematic representation of the experimental protocol described in Materials and Methods (n = 6). (B) Bioluminescence imaging of orthotopically implanted CRC in live, anesthetized mice (left panel) every week, showing measurements (photons/sec) of tumor volume at various time points using live bioluminescence imaging (BLI) at the indicated times (right panel) * indicates significant over control at each time points (Bonferroni Adj (for a total of 15 comparisons) p<0.05). (C) Tumor volumes measured on the last day of the experiment at autopsy using Vernier calipers and calculated using the formula V = 2/3 πr3 (n = 6). * represents significant (Bonferroni Adj (for 3 comparisons) p < 0.05) over vehicle control. (D) Average tumor weight of each group weighed on the last day of the experiment. * represents significant (Bonferroni Adj (for 3 comparisons) p < 0.05) over vehicle control.